Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. more
Time Frame | ACXP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.18% | 0.49% | -1.93% |
1-Month Return | -13% | -3.1% | -3.69% |
3-Month Return | -61.14% | -8.59% | 0.82% |
6-Month Return | -63.43% | -4.57% | 3.51% |
1-Year Return | -82.54% | -0.94% | 21.91% |
3-Year Return | -81.2% | 2.88% | 24.73% |
5-Year Return | -89.76% | 35.84% | 78.4% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 5.93M | 4.60M | 12.81M | 12.09M | 14.58M | [{"date":"2019-12-31","value":40.69,"profit":true},{"date":"2020-12-31","value":31.56,"profit":true},{"date":"2021-12-31","value":87.9,"profit":true},{"date":"2022-12-31","value":82.95,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (5.93M) | (4.60M) | (12.88M) | (12.09M) | (14.58M) | [{"date":"2019-12-31","value":-593125300,"profit":false},{"date":"2020-12-31","value":-460003800,"profit":false},{"date":"2021-12-31","value":-1288070300,"profit":false},{"date":"2022-12-31","value":-1209400000,"profit":false},{"date":"2023-12-31","value":-1457776800,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (5.93M) | (4.60M) | (12.75M) | (12.09M) | (14.58M) | [{"date":"2019-12-31","value":-593125300,"profit":false},{"date":"2020-12-31","value":-460003800,"profit":false},{"date":"2021-12-31","value":-1274769700,"profit":false},{"date":"2022-12-31","value":-1209277600,"profit":false},{"date":"2023-12-31","value":-1457776800,"profit":false}] |
Income Taxes | (5.93K) | (4.60K) | (66.50K) | (1.22K) | (14.58K) | [{"date":"2019-12-31","value":-593425,"profit":false},{"date":"2020-12-31","value":-459804,"profit":false},{"date":"2021-12-31","value":-6650300,"profit":false},{"date":"2022-12-31","value":-122400,"profit":false},{"date":"2023-12-31","value":-1457700,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (5.93M) | (4.60M) | (12.75M) | (12.09M) | (12.72M) | [{"date":"2019-12-31","value":-593125300,"profit":false},{"date":"2020-12-31","value":-460003800,"profit":false},{"date":"2021-12-31","value":-1274769700,"profit":false},{"date":"2022-12-31","value":-1209277600,"profit":false},{"date":"2023-12-31","value":-1272368900,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (5.93M) | (4.60M) | (12.68M) | (12.09M) | (14.58M) | [{"date":"2019-12-31","value":-593125300,"profit":false},{"date":"2020-12-31","value":-460003800,"profit":false},{"date":"2021-12-31","value":-1268119400,"profit":false},{"date":"2022-12-31","value":-1209155200,"profit":false},{"date":"2023-12-31","value":-1457776800,"profit":false}] |
EPS (Diluted) | - | (0.47) | (1.48) | (1.12) | (1.14) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-46.94,"profit":false},{"date":"2021-12-31","value":-148,"profit":false},{"date":"2022-12-31","value":-112,"profit":false},{"date":"2023-12-31","value":-114,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ACXP | |
---|---|
Cash Ratio | 0.00 |
Current Ratio | 0.00 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACXP | |
---|---|
ROA (LTM) | -132.22% |
ROE (LTM) | -346.94% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACXP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.45 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACXP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.76 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Acurx Pharmaceuticals LLC (ACXP) share price today is $0.704
Yes, Indians can buy shares of Acurx Pharmaceuticals LLC (ACXP) on Vested. To buy Acurx Pharmaceuticals LLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACXP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Acurx Pharmaceuticals LLC (ACXP) via the Vested app. You can start investing in Acurx Pharmaceuticals LLC (ACXP) with a minimum investment of $1.
You can invest in shares of Acurx Pharmaceuticals LLC (ACXP) via Vested in three simple steps:
The 52-week high price of Acurx Pharmaceuticals LLC (ACXP) is $5. The 52-week low price of Acurx Pharmaceuticals LLC (ACXP) is $0.68.
The price-to-earnings (P/E) ratio of Acurx Pharmaceuticals LLC (ACXP) is
The price-to-book (P/B) ratio of Acurx Pharmaceuticals LLC (ACXP) is 4.76
The dividend yield of Acurx Pharmaceuticals LLC (ACXP) is 0.00%
The market capitalization of Acurx Pharmaceuticals LLC (ACXP) is $12.66M
The stock symbol (or ticker) of Acurx Pharmaceuticals LLC is ACXP